glp-1 obesity drug news october 2025 drugs are making a dent in the high rate in the U.S. : Shots not-discarded Purchase Plan:3-Months Supply Eli Lilly's GLP-1 outdoes

glp-1 obesity drug news october 2025 drugs are making a dent in the high rate in the U.S. : Shots not-discarded Purchase Plan:3-Months Supply Eli Lilly's GLP-1 outdoes

Eli Lilly's GLP-1 outdoes Novo Nordisk's in trial

Kind Patches’ marketing materials include several claims that could violate ASA guidelines: “92.3% of participants reported fewer cravings” (unsubstantiated efficacy claim) Before/after style testimonials without clinical backing Implications that patches work similarly to prescription medications Claims about “supporting GLP-1 production” without evidence The ASA considers testimonials making medical claims as advertising, regardless of whether they’re “genuine” customer experiences

not-discarded

Purchase Plan:3-Months Supply

Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell